vs
Autolus Therapeutics plc（AUTL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Autolus Therapeutics plc的1.4倍（$30.3M vs $21.2M），REGENXBIO Inc.净利率更高（-221.3% vs -373.3%，领先152.0%），REGENXBIO Inc.自由现金流更多（$-52.8M vs $-72.3M）
Autolus Therapeutics plc是一家临床阶段生物制药企业，专注于研发新一代嵌合抗原受体T细胞（CAR-T）疗法，用于治疗血液恶性肿瘤和实体瘤，拥有多款处于不同临床阶段的肿瘤免疫治疗候选药物管线，面向全球肿瘤治疗市场开展业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
AUTL vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$21.2M
净利率更高
RGNX
高出152.0%
-373.3%
自由现金流更多
RGNX
多$19.5M
$-72.3M
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.2M | $30.3M |
| 净利润 | $-79.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -337.9% | -190.0% |
| 净利率 | -373.3% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 3.6% | -31.2% |
| 每股收益（稀释后） | $-0.30 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AUTLRGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | $21.2M | $29.7M | ||
| Q2 25 | $20.9M | $21.4M | ||
| Q1 25 | $9.0M | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $0 | $24.2M | ||
| Q2 24 | $0 | $22.3M | ||
| Q1 24 | $10.1M | $15.6M |
净利润AUTLRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-79.1M | $-61.9M | ||
| Q2 25 | $-47.9M | $-70.9M | ||
| Q1 25 | $-70.2M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $-82.1M | $-59.6M | ||
| Q2 24 | $-58.3M | $-53.0M | ||
| Q1 24 | $-52.7M | $-63.3M |
毛利率AUTLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率AUTLRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | -337.9% | -176.3% | ||
| Q2 25 | -292.6% | -296.3% | ||
| Q1 25 | -726.3% | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | — | -251.3% | ||
| Q1 24 | -384.1% | -408.8% |
净利率AUTLRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -373.3% | -208.3% | ||
| Q2 25 | -229.0% | -331.8% | ||
| Q1 25 | -781.1% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | — | -237.7% | ||
| Q1 24 | -522.1% | -405.4% |
每股收益（稀释后）AUTLRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $-0.30 | $-1.20 | ||
| Q2 25 | $-0.18 | $-1.38 | ||
| Q1 25 | $-0.26 | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $-0.31 | $-1.17 | ||
| Q2 24 | $-0.22 | $-1.05 | ||
| Q1 24 | $-0.24 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $86.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $265.5M | $102.7M |
| 总资产 | $661.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AUTLRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $86.1M | $274.2M | ||
| Q2 25 | $123.8M | $323.3M | ||
| Q1 25 | $95.8M | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | $657.1M | $255.5M | ||
| Q2 24 | $705.9M | $290.4M | ||
| Q1 24 | $758.5M | $338.7M |
股东权益AUTLRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | $265.5M | $161.5M | ||
| Q2 25 | $346.5M | $213.7M | ||
| Q1 25 | $371.1M | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | $477.0M | $301.4M | ||
| Q2 24 | $527.8M | $348.3M | ||
| Q1 24 | $582.0M | $390.7M |
总资产AUTLRGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | $661.9M | $525.2M | ||
| Q2 25 | $721.0M | $581.0M | ||
| Q1 25 | $746.3M | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | $827.5M | $519.1M | ||
| Q2 24 | $853.6M | $569.4M | ||
| Q1 24 | $901.4M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-72.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | -341.2% | -174.0% |
| 资本支出强度资本支出/营收 | 20.8% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-322.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流AUTLRGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $-67.9M | $-56.0M | ||
| Q2 25 | $-72.8M | $-49.3M | ||
| Q1 25 | $-75.6M | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $-76.7M | $-40.5M | ||
| Q2 24 | $-51.1M | $-45.5M | ||
| Q1 24 | $-40.5M | $-55.5M |
自由现金流AUTLRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $-72.3M | $-56.5M | ||
| Q2 25 | $-80.1M | $-49.7M | ||
| Q1 25 | $-83.8M | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | $-86.3M | $-40.9M | ||
| Q2 24 | $-51.9M | $-46.0M | ||
| Q1 24 | $-41.0M | $-56.0M |
自由现金流率AUTLRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | -341.2% | -189.9% | ||
| Q2 25 | -382.6% | -232.8% | ||
| Q1 25 | -933.1% | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | -406.8% | -358.5% |
资本支出强度AUTLRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | 20.8% | 1.7% | ||
| Q2 25 | 34.8% | 1.8% | ||
| Q1 25 | 91.8% | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | 5.3% | 3.6% |
现金转化率AUTLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AUTL
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
